Atezolizumab Plus Bevacizumab Does Not Improve OS in Renal Cell Carcinoma
The overall survival results were similar between the treatment arms for the overall cohort and for patients with PD-L1+ disease.
Urologic Cancers News
UROLOGIC CANCER ADVISOR
Urologic Cancers News
HLA Variant May Predict Poor Outcomes of Immunotherapy in Cancer Patients
HLA-A*03 was associated with worse progression-free and overall survival.
Tumor Size Affects Survival After Cytoreductive Nephrectomy for RCC
There is no universal approach to patient selection for cytoreductive nephrectomy.
Urine Cytology Rarely Changes Management of Low-Risk NMIBC
Half of urologists order routine urine cytology in patients with low-risk non-muscle-invasive bladder cancer.
Predictors, Outcomes of Bladder Cancer Upstaging Described
Age, lymphovascular invasion, and histology predicted pathologic upstaging among patients with nonmuscle-invasive bladder cancer, a study found.
Relapse of pT0 Bladder Cancer Possible After Radical Cystectomy
Patients with a pT0 tumor at the time of radical cystectomy are still at risk of recurrence and progression and should not be considered cured.
Diabetes Not a Major Driver of Oncologic Outcomes in Renal Cell Carcinoma
Researchers have questioned whether diabetes exerts adverse effects on the prognosis of RCC.
MIBC Tumor Subtypes May Guide Neoadjuvant Chemotherapy Use
Neoadjuvant chemotherapy response rates differed among patients with genomically unstable bladder tumors, urothelial-like bladder tumors, and basal/squamous subtypes.
Belzutifan Demonstrates Efficacy in VHL-Associated Renal Cell Carcinoma
Belzutifan demonstrated activity against both RCC and non-RCC neoplasms associated with VHL disease.
Can Quality of Life Assessments Predict PFS, OS Across Cancer Types?
Recent studies showed associations between quality of life scores and survival in lung and prostate cancer as well as renal cell carcinoma.
Radiation Therapy for Oligometastatic Renal Cell Carcinoma Promising
Serial radiation therapy could provide an alternative to standard-of-care systemic therapy.
Adverse Radiologic and Pathologic Features Predict Worse Survival Outcomes in Small Renal Masses Following Nephrectomy
Researchers hypothesized that adverse radiologic and pathologic T3 features are predictive of worse outcomes in small renal masses.
Cytoreductive Nephrectomy Plus Active Surveillance Benefits Some With Metastatic Renal Cell Carcinoma
The median cancer-specific survival was 56.5 months.
First-Line Nivolumab Plus Ipilimumab May Offer Greater Cost Efficiency Than Pembrolizumab Plus Axitinib in Advanced Renal Cell Carcinoma
The monthly incremental cost per survivor relative to sunitinib for nivolumab plus ipilimumab decreased over time from $90,035 for 12 months to $18,881 for 48 months.
Predicting Long-Term Survival With Nivolumab Plus Ipilimumab in Advanced Renal Cell Carcinoma
Patients with smaller target lesions at baseline were more likely to be long-term survivors.
Oncologists Appear to Prefer IO/IO to IO/TKI Combinations in First-Line Metastatic Renal Cell Carcinoma
The investigators aimed to understand how oncologists decide between IO/IO and IO/TKI treatment options via survey.
Gene Expression Profiling Could Inform Treatment of Non-Clear Cell Renal Cell Carcinoma
Nearly half of non-clear cell renal cell carcinoma samples were classified as proliferative.
Managing Adverse Reactions to Lenvatinib-Pembrolizumab
The median time to first onset of key adverse reactions was within 5 months of starting lenvatinib-pembrolizumab.
5-year Follow-Up: First-Line Nivolumab Plus Ipilimumab vs Sunitinib in Advanced Renal Cell Carcinoma
Investigators presented the longest phase 3 follow-up reported for a checkpoint inhibitor combination therapy in aRCC.
Real-World Characteristics and Treatment Patterns in Advanced Renal Cell Carcinoma Treated With First-Line Avelumab Plus Axitinib
Researchers determined that few patients with poor risk aRCC were receiving first-line avelumab plus axitinib.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...